viewBT Group PLC

Market report: FTSE gains after US regulators approve use of plasma to treat Covid-19

The FTSE has taken its cue from global markets overnight after a coronavirus treatment was approved by US regulators.

BT (LON:BT.A) is gaining after reports it has called in Goldman Sachs following a protracted sell-off of the shares.

Bunzl (LON:BNZL) is in positive territory after it resumed dividend payments following a strong jump in profits after a boost in demand for COVID-19 related products and grocery items.

AstraZeneca (LON:AZN) is up after US President Donald Trump suggested he was willing to fast-track a vaccine being developed by the company with Oxford University.

Meanwhile - Tiziana Life Sciences PLC (LON:TILS, NASDAQ:TLSA) has received a US patent for its TZLS-501 antibody technology being developed to treat the life-threatening effects of the coronavirus (COVID-19).

Elsewhere - Base Resources (LON:BSE) delivered profits of US$39.6mln, and has declared their maiden dividend after the company said its operations in Kenya maintained production during the coronavirus crisis. 

Blackbird Plc (LON:BIRD) has revealed that its cloud video editing platform has been selected by production company Live X for use at the US Democratic National Convention, which was held from Monday to Thursday last week.

Shanta Gold Ltd (LON:SHG) posts revenue of US$73mln from gold production at its mine in Tanzania during the six months to 30 June 2020, up from US$53.6mln last year.

Quick facts: BT Group PLC

Price: 101.15 GBX

Market: LSE
Market Cap: £10.03 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


4D pharma plc merges with SPAC company Longevity Acquisition Corp

4D pharma plc (LON:DDDD) CEO Duncan Peyton tells Proactive the group is to get a cash injection of US$14.6mln through a merger with Longevity Acquisition Corporation (NASDAQ:LOAC), a special purpose acquisition company. Peyton says the merger will accelerate and de-risk 4D's admission to...

3 hours, 58 minutes ago

2 min read